When a country says it wants to provide better healthcare for its population, the question is not limited to hospitals or doctors. It also concerns factories, standards, energy, taxes and the ability to produce basic treatments without relying entirely on imports. In Cameroon, this debate has a very practical dimension: local production covers only a small share of formal medicine consumption, while demand remains strong in Yaoundé and other major cities, and even more so in areas where access to medicines depends on a fragile supply chain.
A pharmaceutical sector at the heart of health sovereignty
Cameroon is part of a region where the pharmaceutical industry is growing, but unevenly. The country belongs to CEMAC, a Central African integration area where local industrialisation remains a stated goal, but one that is still difficult to translate into market share. In the 2020-2030 National Development Strategy, chemicals and pharmaceuticals are among the priority industrial sectors. The document aims to expand local production through import substitution and service to the domestic market, as well as the regional one.
The issue goes beyond industrial statistics alone. It relates to the availability of essential medicines, dependence on foreign purchases and the role of Cameroonian producers in public procurement. It also concerns another fundamental challenge: product quality, oversight of supply chains and the fight against illicit imports. In this regard, Cameroon ratified the treaty establishing the African Medicines Agency in 2021. The treaty’s entry into force was made possible after the deposit of the 15th instrument of ratification, by Cameroon.
The figures behind persistent dependence
The mid-term evaluation report on the 2020-2030 National Development Strategy paints a bleak picture: as at the end of 2025, local pharmaceutical production covered only 5% of national formal consumption. The country has eight industrial units, but this capacity remains insufficient to make an impact on the domestic market. The same document compares this situation with that of other African countries, where levels are higher in Morocco, Tunisia, Senegal and Côte d’Ivoire.
The contrast is all the more striking given that Morocco, according to data cited in the report, has 40 production units covering 65% of the domestic market. Tunisia reaches 45% with 28 units. Senegal, with four units, stands between 10% and 15%. Côte d’Ivoire covers 8% with five units. Cameroon is at the bottom of this group, with eight units and 5% coverage. The report notes, however, that simply counting factories does not tell the whole story: the range of specialisations, formulation capacity, access to inputs and the role of public procurement all weigh heavily on the final result.
Another worrying sign is that public procurement is not yet playing its part as an industrial lever. The report cited refers to just 3.6% of public purchases of pharmaceutical products being sourced from local manufacturers, compared with an average of 11.7% in Africa, 25.3% in India and 59.4% in the European Union. This shortfall matters because the state is often the health sector’s largest buyer able to pay. When public procurement fails to support local industry, it struggles to invest, stabilise its costs and expand its production lines.
Competitiveness, taxation and the market: the real sticking points
The obstacles identified by Cameroonian manufacturers are well known: energy costs, customs duties, transport and, at times, a mismatch between medicines made locally and those on the national list of essential medicines. In practice, producing in Cameroon is not enough. The right molecules must also be produced, at a cost compatible with the purchasing power of households, hospitals and public programmes.
The report also highlights a sensitive issue for the entire health system: in 2012, local production covered only 12.7% of the needs identified on the national list of essential medicines, which contains 473 items. This figure is not comparable with the 2025 rate of 5%, because the calculation bases differ. But it points to the same underlying trend: dependence remains structural, and the road to partial self-sufficiency is still long.
At the macroeconomic level, the sector still accounts for little. The monitoring report cites a contribution from the chemical and pharmaceutical industries that fell from 0.5% of GDP in 2020 to 0.48% in 2023. It also records CFAF 532 billion in imports of chemical products in 2023, or 10.7% of national imports, with pharmaceutical products accounting for 31% of that total. These figures describe an economy in which medicines are still, to a large extent, imported products.
Yaoundé’s targets for 2030
In Yaoundé, the authorities have launched several initiatives. In February 2025, the Ministry of Health held consultations on developing the local pharmaceutical industry. The ministry has spoken of a framework for dialogue, approvals granted to local companies and an ambition to gradually raise coverage to 40% in the coming years. It has also raised the prospect of establishing a Cameroon Medicines Agency, alongside the new continental framework led by the African Union.
The national medicines strategy sets a more specific target: to raise the share of local production in national consumption from 5% to 25% by 2030, and to reduce the estimated share of fraudulent imports of medicines and pharmaceutical products from 40% to 10%. To achieve this, the government is relying on exemptions on the import of certain inputs, restrictions on imports when they compete with local production, and the modernisation of units such as CINPHARM and other players mentioned in the monitoring report.
The stakes for Cameroonians are clear: if local supply grows, the country can better secure its supplies and strengthen Universal Health Coverage, which still relies heavily on import supply chains. If it stagnates, public hospitals and households will remain exposed to shortages, volatile prices and fluctuations in the international market. The pharmaceutical sector is therefore becoming a test of the credibility of the country’s industrialisation policy, as well as of CEMAC’s ability to build stronger regional industries.
Across Africa, Cameroon’s case is a reminder of a shared reality: health sovereignty cannot simply be declared. It is built through factories, standards, coherent public procurement and a regional market capable of absorbing production. That is precisely the spirit of the treaty on the African Medicines Agency, whose entry into force Cameroon helped bring about. The next point of focus will be less a slogan than a simple question: will the second half of the SND30 succeed in transforming a still narrow industrial base into genuine capacity to cover the domestic market?



